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This study was designed to assess the effect of alpha-
and beta-adrenoeeptor antagonist agents on reperfusion
ventricular fibrillation and myocardial metabolic status
preceding the onset of reperfusion ventricular fibrillation
in the isolated LangendortT perfused rat heart. Prazosin
(alphaj-antagonlst), yohimbine (alphaj-antagonlst) and
phentolamine (alphaj- and alphaj-antagonlstj protected
against reperfusion ventricular fibrillation, the median
effective dose (EDso) values being 2.0, 0.7 and 2.5 #tmol/
liter, respectively, when given before coronary artery
ligation. The ability of alpha-antagonist agents to pre-
vent reperfusion ventricular fibrillation appeared to be
the consequence of alpha-adrenoceptor antagonism or
the consequence of "membrane-stabilizing activity," or
both. Reserpinization before reperfusion reduced but
did not eliminate reperfusion ventricular fibrillation.
Relative to the reported dissociation constants of myo-
cardial alpha-adrenoceptors, yohimbine (alpha2-antag-
onist) appeared more active; such antiarrhythmic po-
tential apparently has not been reported previously. The
beta-adrenoceptor antagonist agents dI-propranolol (EDso
value, 3 #tmol/liter) and metoprolol in high concentra-
tions (EDso value, SO #tmol/liter) prevented reperfusion
Both coronary artery occlusion and subsequent reperfusion
of the acutely ischemic myocardium predispose to the de-
velopment of ventricular arrhythmias, including ventricular
fibrillation . Experimental evidence suggests that enhanced
adrenergic activity (1,2), in conjunction with metabolic and
biochemical sequelae (3) of acute myocardial ischemia, plays
an important role in the genesis of ventricular arrhythmias
during the period of coronary artery occlusion.
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ventricular fibrillation, whereas atenolol was virtually
without effect. d-Propranolol (EDso value, 2.5 #tmol/li-
ter), the propranolol isomer with modest beta-antagonist
activity but with marked membrane-stabilizing activity,
evoked protection equivalent to that of racemic pro-
pranolol. Beta-adrenoceptor antagonists did not appear
to prevent reperfusion ventricular fibrillation as a con-
sequence of receptor antagonism but rather by mem-
brane-stabilizing activity.
Some circumstantial association was evident between
improved metabolic status on reperfusion, in preser-
vation of tissue levels of adenosine triphosphate and
phosphocreatine, reduction of tissue levels of lactate and
cyclic adenosine monophosphate and protection against
reperfusion ventricular fibrillation. However, agents af-
fording a similar degree of metabolic preservation were
associated with different degrees of protection against
reperfusion ventricular fibrillation. Of the four possible
protective procedures: alpha-receptor antagonism, beta-
adrenoceptor antagonism, membrane-stabilizing activ-
ity and metabolic preservation, alpha-receptor antago-
nism and membrane-stabilizing activity most warrant
further evaluation, especially in other species.
The release of endogenous and systemic catecholamines
(2) after coronary occlusion and the accumulation of cyclic
adenosine monophosphate (cAMP) (4,5) in the ischemic
myocardium are considered to predispose to the occurrence
of slow response action potentials (6,7) . Therefore, it has
been argued that beta-adrenergic receptor stimulation may
predispose to the development of ischemic arrhythmias by
promotion of the slow response . Alpha-adrenergic receptor
stimulation, on the other hand , has only a small effect on
the slow response (8) , although this may account in part for
the proposal that alpha-stimulation enhances the influx of
calcium in ventricular muscle (9). The reduction of myo-
cardial high energy phosphate content (10, II) and the in-
crease in lactate concentration (12) in the ischemic myo-
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cardium have also been thought to predispose to ventricular
arrhythmias by shortening the action potential duration.
In contrast to ischemic arrhythmias, the role of adren-
ergic, biochemical and metabolic influences on reperfusion
ventricular arrhythmias has not been clearly defined. These
factors assume importance because the precise mechanism
of reperfusion ventricular fibrillation is unclear and recent
evidence (13) suggests that the severity of reperfusion ven-
tricular arrhythmias may be dependent on rhythm distur-
bances during the antecedent period of coronary occlusion,
although the mechanisms might differ.
Therefore, the present study was designed to characterize
the metabolic and biochemical status before the onset of
reperfusion ventricular fibrillation and assess the role of
alpha- and beta-adrenergic influences on reperfusion ven-
tricular arrhythmias and metabolic status. Alpha-adrenergic
receptors are classified into subtypes 1 and 2 (14), and
because preliminary evidence by Sheridan et al. (15) indi-
cates that alpha, responses may play an important role in
the genesis of reperfusion arrhythmias, we paid special at-
tention to alpha-adrenoceptor antagonism, comparing it with
the effects of alpha--adrenoceptor antagonism. We also in-
vestigated the effect of beta-adrenoceptor antagonism and
assessed the importance of the" membrane-stabilizing prop-
erty" peculiar to some beta-antagonists. The isolated Lang-
endorff perfused rat heart subjected to left main coronary
artery ligation and reperfusion was used because of the
consistent occurrence and predictable time of onset of re-
perfusion ventricular fibrillation (16).
Methods
Experimental preparation. Long-Evans rats (weight 275 to
375 g) were anesthetized with ether and their hearts were removed
after injection of 100 units of heparin into the femoral vein. The
hearts were immediately arrested in ice-cold Krebs-Henseleit so-
lution, mounted on a Langendorff nonfunctioning aortic retrograde
perfusion system modified to contain two perfusate reservoirs and
perfused at a constant filling pressure of 100 cm water. The heart
was enclosed in a glass water jacket maintained at 37°C. The
perfusate was modified Krebs-Henseleit solution (potassium ion
[K + 14.8 mmollliter; substrate glucose, Il.l mmollliter aerated
with 95% oxygen and 5% carbon dioxide, and maintained at a
constant temperature of 37°C). Lubbe et al. (16) showed that hearts
perfused with Krebs-Henseleit solution with a K + level of 4.8
mrnol/liter are associated with a 100% incidence of reperfusion
ventricular fibrillation.
A 5-0 silk suture was placed deep to the left main coronary
artery within 2 mm of where it emerged adjacent to the left atrium
(17). A thin stainless steel wire was inserted into the right ven-
tricular free wall superficially as one electrode; the other electrode
was clamped onto the metal aortic perfusion cannula. The elec-
trocardiogram obtained was used to evaluate heart rate and rhythm.
Coronary flow rates were measured by collecting the coronary
effluent into a graduated measuring tube over a I minute period.
Heart rate and coronary flow were recorded during a 15 minute
period of stabilization. Complete coronary artery occlusion was
then produced by tightening the previously placed ligature over a
short length of polyvinyl tubing that partially encompassed the left
main coronary artery. Successful ligation was indicated by a de-
crease of the coronary flow rate of at least 25% of the basal rate
and the darkening of most of the free left ventricular myocardium.
With use of these criteria, 40 to 50% of the left ventricle is usually
rendered ischemic (17).
After 15 minutes of coronary artery occlusion, the ligature was
divided using a surgical blade that was drawn along the polyvinyl
tubing to avoid injury to underlying myocardium or coronary ar-
tery. The experiment was terminated 10 minutes after the onset
of reperfusion, The heart rhythm was monitored by continuous
electrocardiographic recording throughout the period of coronary
occlusion and on reperfusion.
In a separate series ofexperiments, hearts were freeze-clamped
using precooled Wollenberger tongs (18) for biochemical analysis
at the end of the period of coronary artery ligation to assess the
metabolic status at this time point, and 10 seconds after the onset
of reperfusion. This time sequence was chosen because reperfusion
ventricular fibrillation occurs approximately 15 seconds after the
onset of reperfusion. In the hearts clamped at the end of the period
of coronary artery ligation, the introduction of disulfine blue dye
into the aortic perfusion cannula just before clamping enabled
separation of ischemic from nonischemic tissue. Disulfine blue dye
binds with oxygen and therefore the perfused nonischemic zone
is rendered blue while the ischemic zone does not take up the
stam.
High energy phosphates, glycogen, lactate and cyclic AMP
were analyzed as previously described (19-22). In some experi-
ments, rats were pretreated with reserpine by the procedure of
Gaudel et al. (23), which severely depletes the myocardium of
both norepinephrine and epinephrine.
Chemical agents. Compounds were obtained in powder form:
metoprolol (Ciba-Geigy), dl-propranolol, d- and l-propranolol iso-
mers (ICI), prazosin (Pfizer) and yohimbine (Sigma Corporation
Ltd., USA). Phentolamine hydrochloride was obtained as a so-
lution (Boots). Five minutes before and 5 minutes after coronary
artery ligation, perfusion was switched from the reservoir con-
taining modified Krebs-Henseleit solution to the other reservoir
where the respective pharmacologic agent was present in the re-
spective concentration. Compounds were freshly prepared for each
experiment.
Analysis of arrhythmias. Ventricular tachycardia was diag-
nosed if more than three consecutive morphologically similar ven-
tricular extrasystoles occurred. Ventricular fibrillation was di-
agnosed if more than six consecutive ventricular complexes showed
total irregularity of morphology. During the period of coronary
artery occlusion, antiarrhythmic activity was assessed primarily
by reduction in the incidence of ventricular fibrillation, ventricular
tachycardia and ventricular extrasystoles. Ventricular antiar-
rhythmic activity after reperfusion was assessed by prevention of
the occurrence of ventricular fibrillation and also by reduction of
the mean duration of reperfusion ventricular fibrillation and ven-
tricular tachycardia (that is, spontaneous reversion to sinus rhythm
during the 600 second period of reperfusion).
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Statistical methods. Results are given as mean ± standard
error of the mean for the number of experiments. The number (n)
of heartsperfused in each series ranged from 10to 20. Probability
[p] values were calculated with Student's t test using two-tailed
values as corrected for unequal variances. Probability values less
than0.05 indicatedsignificance except whenmultiplecomparisons
required Bonferroni's corrections(24). The Fisher's exact test (25)
wasappliedto assess thedifferencesin the incidenceof reperfusion
ventricular fibrillation betweengroups. Probabilityvaluesless than
0.05 again indicated significance.
Criticism of Model
The isolated Langendorff perfused rat heart model has both
advantages and limitations.
Advantages of model. a) The consistentoccurrence of reper-
fusionventricularfibrillation (100%), the predictable time of onset
of such fibrillation and the consistent sinus rhythm in the preli-
gationperiodmakethis an excellentmodel to assessantiarrhythmic
efficacy. b) The concentrations of pharmacologic agents perfusing
the heart are maintainedat constant levels. c) The metabolic con-
sequences of acute myocardial ischemia and reperfusion of the
acutely ischemic myocardium may be correlated with ventricular
arrhythmias.
Limitations of model. a) The isolated heart is devoid of ex-
ternal autonomic nervous control. Nevertheless, there are endog-
enous catecholamines that are similar in content to the heart in
situ and only mildly reduced with coronary ligation (26). b) The
isolated heart has an abnormally high coronary flow rate as a
consequence of absenceof hemoglobinin theperfusion fluid. c)The
high preligation heart rate (approximately 300 beats/min) makes
it difficultto correctlyclassify the natureof some tachycardias (up
to 800 beats/min) (26). d) The aortic-perfused heart performs no
volume work as there is no left atrial filling. e) As in any model,
effectsmaybe species-specific, especiallyin thedensityandnature
of adrenoceptors.
Results
Effect of Coronary Artery Ligation and Reperjusion
Coronary flow. Ligation of the left main coronary artery
resulted in a decrease in the mean total coronary flow rate
(ischemic and nonischemic flow) in control hearts from 10.3
± 0.5 to 5.4 ± 0.4 ml/min (p < 0.001). On reperfusion,
there was an immediate reversal of the coronary flow rate
to 12.1 ± 0.9 ml/min (p < 0.02), a value significantly
higher than that found before coronary ligation. This prob-
ably reflects the phenomenon of reactive hyperemia.
In hearts perfused with alpha- or beta-adrenoceptor an-
tagonists, the mean total coronary flow rates during acute
myocardial ischemia and on reperfusion were similar or, in
some series, significantly lower than the mean coronary flow
rate found in the control series (data available on request),
suggesting that the antiarrhythmic activity of these agents
was not the consequence of improved coronary perfusion.
However, any redistribution of coronary flow cannot be
excluded because only total coronary flow (ischemic and
nonischemic) was measured.
Ventricular arrhythmias. During the 15 minute period
of coronary artery occlusion, the following ventricular ar-
rhythmias occurred in the control series (n = 18): 100% of
hearts developed ventricular premature systoles (mean num-
ber/IS min = 46 ± 10), 89% developed ventricular tachy-
cardia (mean duration 34 ± 6 seconds) and II % developed
ventricular fibrillation. A decrease in the mean heart rate
occurred during coronary artery occlusion from 264 ± 10
(preligation) to 214 ± 8 beats/min (postligation; paired t
test, p < 0.01). Within 15 seconds of reperfusion of the
acutely ischemic myocardium, ventricular fibrillation oc-
curred in all hearts (100% incidence). Analysis of the heart
rhythm during the first 600 seconds of reperfusion showed
that the mean duration of ventricular fibrillation combined
with ventricular tachycardia over the period was 580 ± 10
seconds.
Effect of Alpha-adrenoceptor Antagonist Agents
Coronary occlusion. Perfusion with yohimbine (alphar
antagonist), 0.1 to 5 J,tmolliiter, and phentolamine (alphal-
and alphaj-antagonist), 0.1 to 100 J,tmolliiter, resulted in a
concentration-related decrease in the incidence of ventric-
ular arrhythmias during the phase of acute coronary occlu-
sion. Ventricular fibrillation did not occur in hearts perfused
with even the lowest concentrations studied (0.1 J,tmol/liter)
of both phentolamine and yohimbine, whereas with pra-
zosin, ventricular fibrillation was not evident when concen-
trations of 1 J,tmol/liter or higher were used. In the control
of ventricular tachycardia during ischemia, the EDso values
obtained from the log dose-response curves were yohim-
bine, 0.50 J,tmol/liter; prazosin, 2.0 J,tmolliiter and phen-
tolamine, 5 J,tmolliiter, respectively (Table 1).
Reperfusion. All three alpha-adrenergic antagonist agents
produced a concentration-dependent reduction in the inci-
dence of reperfusion ventricular fibrillation, the EDso values
obtained from the log dose-response curves were yohim-
bine, 0.70 J,tmolliiter; prazosin, 2.0 J,tmol/liter and phen-
tolamine, 2.5 J,tmoilliter, respectively (Tables I and 2).
Complete protection against reperfusion ventricular ar-
rhythmias occurred with the following concentrations (umoll
liter): yohimbine,S; prazosin, 20 and phentolamine, 50.
The mean heart rate was reduced in all series exhibiting
complete protection. Rates were (beats/min): yohimbine,
180 ± 10 (p < 0.05); prazosin, 175 ± 8 (p < 0.01) and
phentolamine, 170 ± 12 (p < 0.01) versus control series,
214 ± 8. The reduction in the mean duration of reperfusion
ventricular fibrillation and ventricular tachycardia is shown
in Figure 1.
Effect of Beta-adrenoceptor Antagonist Agents on
Ventricular Arrhythmias
According to the dose-response curve test of the beta-
agonist isoproterenol, a concentration of 0.1 J,tmolliiter ex-
hibited near maximal cardiac effects, that is, an increase in
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Table 1. Effect of Alpha- or of Beta-adrenoceptor Antagonist Agents on Ischemic and Reperfusion Ventricular Arrhythmias
Agent (molar)
n
VT + VF
Duration
Ischemia
VT
Incidence (%)
VT + VF
Duration
Reperfusion
VF
Incidence (%)
Alpha-adrenoceptor Antagonists
Phentolamine
10- 7 5 53 :±: 17 100
5 x 10- 7 10 27 :±: II 70
10- 6 10 26 :±: 5 90
5 X 10- 6 8 8 :±: 5 50
10- 5 13 2 :±: I 38
5 x 10- 5 9 0 0
Prazosin
5 x 10-7 8 35 :±: 6 100
10- 6 12 16 :±: 5 67
5 x 10- 6 9 15 :±: 10 33
10- 5 II 8 :±: 6 27
2 x 10- 5 7 0 0
Yohimbine
10- 7 9 9 :±: 3 67
5 x 10- 7 10 9 :±: 4 50
10-6 14 I :±: I 15
2.5 x 10- 6 9 0 0
5 X 10- 6 9 0 0
Beta-adrenoceptor Antagonists
dl-propranolol
10- 7 4 27 :±: II 100
5 x 10- 7 4 25 :±: 9 75
10-6 7 15 :±: 9 57
2.5 x 10-6 8 12 :±: 5 50
5 X 10- 6 9 9 :±: 4 44
10- 5 8 0 0
d-propranolol
10-6 6 13 :±: 7 50
2.5 X 10- 6 8 20 :±: 8 63
5 x 10- 6 8 8 :±: 4 13
10- 5 7 0 0
Metoprolol
10- 6 4 44:±: 20 100
10-5 8 8 :±: 3 63
5 x 10- 5 6 15 :±: 5 83
10- 4 8 0 0
2 X 10- 4 6 0 0
4 X 10- 4 5 0 0
Atenolol
5 x 10- 7 5 39 :±: 29 60
10- 6 8 60:±: 12 67
5 x 10- 6 4 49 :±: 17 75
10- 5 6 25 :±: 8 100
10- 4 9 18 :±: 7 78
Class I Antiarrhythmic Agent
552 :±: 15 100
407 :±: 83 80
301 :±: 77 70
132 :±: 72 38
31 :±: II 28
0 0
551 :±: 14 100
424 :±: 72 75
126 :±: 74 22
38 :±: 34 18
0 0
350 :±: 85 78
289 :±: 89 60
167 :±: 64 36
0 0
0 0
593 :±: 3 100
587 :±: 9 100
415 :±: 81 86
171 :±: 63 63
28 :±: 12 11
0 0
385 :±: 87 83
69 :±: 33 50
15 :±: 8 0
0 0
589 :±: 5 100
486 ± 57 100
150 :±: 57 50
0 0
5 :±: 5 0
0 0
600 :±: 0 100
596 :±: 4 100
597 :±: 4 100
543 :±: 21 100
417 :±: 51 100
Lidocame*
2 x 10- 5
3.8 X 10- 5
I X 10- 4
No data
No data
No data
80
50
5
No data
No data
No data
100
50
o
Isolated rat hearts were perfused in retrograde manner via the aorta for 15 minutes before coronary artery ligation. after 15 rnmutes of coronary occlusion. the ligature
was released and the rhythm monitored for a further 10 minutes (600 seconds). Drugs were added 5 mmutes before coronary hgation. In control senes (n = 18). ventncular
arrhythmias were: I) ischerma VT 89% and VF 11%; and 2) reperfusion VF 100%. Mean duration of reperfuvron VT + VF = 580 :t 10 seconds
n = number of hearts In each group. VF = ventncular fibnllation; VT = ventncular tachycardia; VT + VF = combined duration of these arrhythmias (For duficulnes
In distmctron. see Didier et al. [26].) (*Adapted from Lubbe et al. [16J With perrnissron.)
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Table 2. Comparison of Median EffectiveConcentration (EDso) of Alpha- or Beta-adrenoceptor Antagonist Agents on the Incidence
of Reperfusion Ventricular Fibrillation in Comparison With Published Values for Inhibition or Dissociation Constants (K, or Ks),
Based Chiefly on Displacement of Radioligands From Rat Myocardial and Other Tissues (for relation between Ko and K" see
Maguire et al. [39])
ED50
(M)
Kr for
Displacement of
Specific al
Antagonist (29)
(M)
Ko for a2
Radioligand
Binding (30)
(M)
KDfor {31
Radioligand
Binding
(M)
Ko for Propranolol
Binding Site of Dog
Heart Measured by
Antibody Techniques
(42)
(M)
Alpha-adrenoceptor Antagonists
Phentolamine (al and a2)
Prazosin (ad
Yohimbine (a2)
2.5 X 10- 6
2 X 10- 6
7 X 10- 7
5 X 10- 8
3 X 10- 10
9 X 10- 7 2 X 10- 8 (initial)
8 x 10- 10 (final)
dl-Propranolol
d-Propranolol
Metoprolol
Atenolol
2.0 X 10-6
2.5 X 10- 6
5 X 10- 5
I X 10- 4
Beta-adrenoceptor Antagonists
2 X 10- 5
3 X 1O- 7t
7.5 X 1O- 7t
22 X 10- 9
4 X 10- 6
* Data for rat heart assuming that dl-propranolol has half the potency of I-propranolol (adapted from Maguire et al [39] With permission), t data for gumea-pig left
ventncle (adaptedfrom Hedberget al. [40] with permission); :j:data for immature rat erythrocytes (adapted from Palm [41]) With permission).
KD = values for antibody bmdmgof dl-propranolol presumed to be double that of I-propranolol; M = molar, - = no data.
both the heart rate and coronary flow rates. The effects of
three beta-antagonists, metoprolol, atenolol and propranolol
(added 5 minutes before coronary ligation), on the arrhyth-
mias of coronary occlusion and reperfusion were as follows.
Metoprolol. Metoprolol, 10 p,molliiter, exhibited com-
plete antagonism against the cardiac effects of isoproterenol,
Figure 1. The duration of reperfusion in the experimental protocol was
600 seconds. The control senes (not depicted) had a mean duration of
reperfusion ventricular fibrillation (VF) and ventricular tachycardia (VT)
of 580 ± 10 seconds for virtually the entire period of reperfusion. An-
tiarrhythmic activity was assessed also by a reduction in the mean duration
of these arrhythmias during the 600 seconds of reperfusion. Although lower
concentrations of adrenoceptor antagonist may not have reduced the Ill-
cidence of reperfusion ventricular fibrillation, antiarrhythmic activity was
manifest by their abihty to cause spontaneous reversion from ventricular
fibrillation to sinus rhythm during the 600 second period of reperfusion.
Thus, prazosm, yohimbine and phentolamine produced concentration-de-
pendent decreases in the mean duration of reperfusion ventricular fibril-
lation and tachycardia.
5 100s
:>
'C
c:
~ 0·5 10 5fJmol!hter
• o[)o • Phentolamine
_ Yohimbine
-x- Prazostn
10 50
0.1 p,mol/liter, as judged by the absence of an increase in
heart rate and coronary flow.
Occlusion. Metoprolol, 10 p,mollliter, did not reduce the
incidence of ventricular tachycardia but decreased the mean
duration of ventricular tachycardia. The median effective
dose (EDso) value for reduction in the incidence of ventric-
ular tachycardia was 50 p,mollliter. Ventricular arrhythmias
were absent when the perfusate contained metroprolol in a
concentration of 100 p,molliiter (Table I).
Reperfusion. Metoprolol, 50 to 100 p,molliiter, de-
creased the incidence of reperfusion ventricular fibrillation,
and the EDso value obtained from the log dose-response
curve was 50 p,molliiter (Fig. 2). The EDso values of me-
toprolol for reduction in incidence of ventricular tachycardia
during occlusion and reperfusion ventricular fibrillation were
identical. Reperfusion ventricular fibrillation was not en-
countered with metoprolol, 100 p,mollliter (Fig. 2). The
mean heart rate of hearts perfused with metoprolol, 100
p,mollliter, was 165 ± 7 beats/min. Because metoprolol
protected against reperfusion ventricular fibrillation in a much
higher concentration (50 to 100 p,molliiter) than that which
provided complete beta-adrenoceptor antagonism (Table 2),
we compared the antiarrhythmic effects of two other com-
pounds, atenolol and propranolol, with their beta-antagonist
effect.
AtenoIoI. This highly selective beta,-antagonist, which
does not have membrane-stabilizing activity when used in
a dose of 30 p,molliiter, completely antagonized the cardiac
effects of isoproterenol, 0.1 p,mollliter. However, atenolol,
0.5 to 100 p,molliiter, did not protect against ventricular
arrhythmias during the period of coronary artery occlusion;
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Figure 2. Racemic propranolol, d-propranolol and metoprolol in high
concentrations decreased the mean duration of reperfusion ventricular fi-
brillation and tachycardia. d-Propranolol, the propranolol Isomer with only
partial beta-antagonist activity but with marked membrane-stabilizing ac-
tivity, exhibited antiarrhythmic activity similar to that of racemic pro-
pranolol. Atenolol was ineffective except at the highest concentration of
100 /-Lmolliiter. Minimal reduction in reperfusion ventricular fibrillation
and tachycardia occurred (p < a 02).
Figure 3. The administration of phentolamine 5 minutes after coronary
artery ligation (compared with administration 5 minutes before ligation)
shifted the dose-response curve to the right for the reduction in a) incidence
of reperfusion ventricular fibrillation. and b) mean duration of reperfusion
ventricular fibrillation and ventricular tachycardia. Only data for the latter
are shown.
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Figure 4. The ininanon of metoprolol 5 minutes after coronary artery
ligation (compared with initiation 5 mmutes before ligation) shifted the
dose-response curve to the right for reduction III a) incidence of reperfusion
ventricular fibrillation, and b) mean duration of reperfusion ventricular
fibrillation and ventricular tachycardia. Only data for the latter are shown.
(100 p,mollliter), producing total antiarrhythmic protection
in this experimental situation.
Because of the high drug concentration required for an
antiarrhythmic effect when added after coronary ligation,
the combination of alpha- and beta-antagonism was studied.
Metoprolol, 100 p,mollliter, plus phentolamine, 100 p,moll
liter, exerted total protection against reperfusion ventricular
fibrillation, thereby acting more effectively than either agent
in the respective concentrations. However, this combination
was associated with marked bradycardia (120 ± 8 versus
control 214 ± 8 beats/min, p < 0.0001).
Myocardial Metabolism
Coronary occlusion. Fifteen minutes after the onset of
acute coronary artery ligation in control hearts, that is, im-
mediately before the onset of reperfusion, the tissue met-
there was a 90% incidence of ventricular extrasystoles (fre-
quency 35 ± 6/15 min) and 83% incidence of ventricular
tachycardia (control incidence 89%, mean duration 40 ±
6 seconds). Atenolol, 0.5 to 100 p,mollliter, did not reduce
incidence of reperfusion ventricular fibrillation (Table 1).
Propranolol. dl-Propranolol, 0.5 p,molliiter, exerted
complete beta-antagonism against the cardiac effects of iso-
proterenol, 0.1 p,mollliter, but did not protect against re-
perfusion ventricular fibrillation. dl-Propranolol in a higher
concentration of 10 p,molliiter gave complete protection
(Fig. 2). d-Propranolol, 10 p,mol/liter, the isomer possess-
ing membrane-stabilizing activity (27), and with only little
of the beta-blocking activity of the racemic mixture (27),
also totally protected against reperfusion ventricular fibril-
lation (Fig. 2). The reduction in the mean duration of re-
perfusion ventricular fibrillation and ventricular tachycardia
evoked by beta-antagonists is shown in Figure 2.
Effect of Drugs When Added 5 Minutes After
Coronary Artery Ligation
Coronary occlusion. Phentolamine, metoprolol and the
combination of phentolamine and metoprolol reduced du-
ration and incidenceof ventriculartachycardiaand also number
of ventricular systoles (Table I).
Reperfusion. The EDso value of phentolamine and me-
toprolol for decreasing the incidence of reperfusion ven-
tricular fibrillation shifted from 2.5 and 50 p,mollliter, re-
spectively (drug added 5 minutes before ligation), to 120
and 150 p,moIl1iter, respectively (drug added 5 minutes after
ligation) (Fig. 3 and 4). The EDso values of both phentol-
amine and metoprolol closely approximated the concentra-
tion of phentolamine (50 p,mollliter) and metoprolol
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abolic profile in the ischemic myocardium showed the ex-
pected depletion of high energy phosphate and glycogen
content and accumulation of lactate and cyclic AMP (data
available on request).
The administration of phentolamine, metoprolol or the
combination of these two agents (all 100 JLmol/liter) begun
5 minutes after coronary artery ligation reduced the marked
depletion of phosphocreatine and glycogen content but did
not change the extent of accumulation of tissue cyclic AMP
in the ischemic myocardium (data available on request).
Reperfusion. Ten seconds after the onset of reperfusion
(that is, immediately before the onset of reperfusion ven-
tricular fibrillation), the metabolic changes during the isch-
emic period were somewhat worsened by the short period
of reperfusion (Table 3). Hearts perfused with either me-
toprolol, 100 JLmollliter, phentolamine, 100 JLmollliter, or
the combination, 100 JLmollliter, 5 minutes after the onset
of coronary artery ligation were associated with improved
metabolic status on reperfusion, such as higher tissue levels
of adenosine triphosphate and phosphocreatine and lower
levels of lactate and cyclic AMP (Table 3). Metoprolol was
least effective in the prevention of reperfusion arrhythmias,
but the preservation of adenosine triphosphate content and
the reduction in tissue lactate and cyclic AMP content were
similar to that of phentolamine or phentolamine plus
metoprolol.
All three series were associated with a slower heart rate
than that found in the control series (214 ± 8 beats/min).
Heart rates were reduced as follows: metoprolol, 164 ± 7
(p < 0.01); phentolamine, 140 ± 9 (p < 0.001) and phen-
tolamine plus metoprolol, 120 ± 8 (p < 0.001) (p values
versus control hearts).
Table 3. Effect of Adrenoceptor Antagonist Agents on Metabolic Status of Whole Heart Within 10 Seconds of Reperfusion: Relation
to Reperfusion Ventricular Fibrillation and Ventricular Tachycardia
VF
+
VF VT
ATP PCr Glycogen Cyclic AMP Lactate Incidence Duration
(umol/g) (umol/gj (umol/g) (nmollg) (umol/g) (%) (seconds)
I. Nonligated hearts 4.5 ± 0.1 4.1 ± 0.2 17.3 ± 1.0 0.4 ± 0.02
2. Ligated hearts 3.1 ± 0.2 2.7 ± 0.1 9.4 ± 0.8 042 ± 0.02
p vs I <0.001 <0.001 <0.001
3. Ligated + reperfused hearts 2.8 ± 0.1 1.9±0.1 8.4 ± 1.1 0.49 :!: 003 8.7 ± 0.4 100 580 :!: 10
P vs I <0.001 <0.001 <0.001 <0.001
4. Ligated + reperfused hearts
+ additions
a. Metoprolol (100 /-Lmollliter)
after CAL 3.1 :!: 0.1 3.0 :!: 0.1 10.2 :!: 1.4 0.39 :!: 0.02 7.1 :!: 0.7 100 58 :!: 12
P vs 3 <0.05 <0.001 NS <0.05 NS NS <0.001
b. Phentolamine (100 /-Lmoll
liter) after CAL 3.2 ± 0 I 3.7 :!: 0.2 8.8 ± 1.3 039 :!: 0.02 73 ± 04 50 8 ± 2
p vs 3 <0.01 <0.001 NS <0.05 <005 <0.05 <0.001
c. Phentolamine + metoprolol
(100 /-Lmolliiter) after
CAL 3.6 ± 0.1 4.0 ± 0.2 11.7 :!: 1.1 0.41 :!: 002 5.7 ± 0.7 0 I ± I
p vs 3 <0.01 <0.001 NS NS <0.005 <0.01 <0005
d. Phentolamine (10 /-Lmoll
liter) before CAL 3.4 ± 0.2 3.1 ± 0.2 13.6 ± 1.9 6.3 ± 0.8 28 31 ± 11
p vs 3 <0.01 <0.001 <0.01 <0.05 <0.01 <0.001
e. Prazosin (10 /-Lmoi/liter)
before CAL 3.5 ± 0.1 3.4 ± 0.2 12.6 :!: 0.8 5.6 ± 06 18 38 ± 34
p vs 3 <0.01 <0.001 <0.05 <0 DOl <0.01 <0.001
f. Yohimbine (I /-Lmoi/liter)
before CAL 3.9 :!: 0.1 3.9 ± 0.2 13.8 ± 1.5 4.6 ± 06 36 167 ± 64
p vs 3 <0.0001 <0.0001 <0.05 <0.001 <0.05 <0.001
Series 1. The nonligated hearts represent hearts perfused for 30 mIDutes and then clamped for biochemical analysis
Series 2 Ligated hearts represent hearts perfused for 15 minutes. then subjected to left main coronary artery liganon and clamped for biochemical analysts at the end of
the 15 rnmute period of ligation (total duration 30 minutes). i e . Immediately before onset of reperfusion
Series 3 Ligated and reperfused hearts represent hearts perfused for 15 minutes, subjected to left coronary lrganon for 15 minutes. then reperfused and clamped after 10
seconds (total duration 30 minutes, 10 seconds), immediately before onset of reperfusion ventricular fibnllanon that occurs withm 15 seconds of reperfusion
Series 4. LIgated and reperfused hearts ID whrch drugs were added either 5 minutes after hgauon (4a. b. c) or 5 mmutes before ligation (4d. e. f)
Mean ± for 8 to 20 hearts; p values for ligation and reperfusion and drug versus hganon and reperfusion Values represent mean ± standard error of the mean. all values
expressed in terms of fresh weight (= dry weight X 5), glycogen expressed as nmol glucose equivalent
AMP = adenosine monophosphate; ATP = adenosine triphosphate: CAL = coronary artery ligation. NS = not sigruficant. p ~ probabihty: PCr = phosphocreatme,
VF = ventricular fibnllanon; VT = ventricular tachycardia, - = absence of data
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Effect of phentolamine, prazosin and yohimbine when
added 5 minutes before coronary artery ligation. Hearts
perfused with phentolamine, 10 ILmol/liter; yohimbine , I
JLmollliter; and prazosin, 10 JLmol/liter, begun 5 minutes
before coronary artery ligation were associated with pres-
ervation of adenosine triphosphate, phosphocreatine and
glycogen; moreover, tissue lactate levels were reduced (Ta-
ble 3).
Because both yohimbine , I ILmollliter, and phentolam-
ine , 10 umol/l irer. were not associated with any sign ificant
reduction in the heart rate in comparison with the control
series, the impro ved metabolic status in these series was
probably not the consequence of a slow heart rate.
Reserpine pretreatment . In this group, tyramine stimu-
lation of the perfused heart failed to increase the heart rate
as in control hearts , showing effective depletion of cate-
chol amine s. The duration of reperfusion ventricular tachy-
cardi a-fibrillati on was reduced from 529 ± 66 (n = 9
control hearts ) to 30 I ± 68 seconds (n = 12 reserpine-
treated hearts , p < 0 .03).
Discussion
Reperfusion ventricular fibrillation may occur on regres-
sion of coronary artery spasm or after revascularization of
an acutely occluded coronary artery . The relevance of re-
perfusion ventricular fibrillation stems from the proposal
that it may be the underlying mechanism of sudden death
in patients with coronary artery disease who have no evi-
dence of coronary occlu sion or acute myocard ial infarction.
Role of alpha-adrenergic responses. At present there
are discordant observations as to the presence of alpha j-
and alphaj -receptor subtypes in the rat myocardium . Wil-
liam s et al. (28) and Steinberg and Bilezikian (29) have
characterized the myocardial alpha-receptors as being pri-
marily of the alpha , subtype; the apparent inhibitory con-
stant s (study of Ste inberg) being compatible with the ex-
pected order of potenc y of alpha j- adrenoceptors: prazo sin ,
3 x IO- IOM; phentolamine , 5 x IO- HM and yohimbine,
9 x 1O - 7M.
In contrast to these findings, Guicheney et al. (30) dem-
onstrated that the rat myocardium contains an equal number
of alpha ,- and alpha--receptors. Their study showed pre-
synaptic binding, resembling alpha--receptor binding , with
initial and final dissociation constant s of 2.3 x IO- HM and
8.3 x IO- IOM for yohimbine .
Alpha}" and alphas- mediated response. A mechanism
specific to alpha-receptors, sugge sted previously by Sher-
idan et al. ( 15) and Corr and Crafford (3 1), appears unlikely
becau se the concentration of prazo sin required to exert pro-
tection was 10-fold higher than that of yohimbine . Accord-
ing to the dissociation constants for alpha.-adrenergic re-
ceptors, prazo sin should have been more effective at a much
lower concentration than yohimbine in the prevention of
reperfusion ventricular fibrillation . It may, therefore , be
asked whether the protective mechanism is specific to the
alpha-receptor. If this were so, prazosin, the specific alpha-
antagonist, would be expected to be markedly less potent
than yohimbine , the specific alpha--antagonist , which is not
the case (Table 2).
Our findings, theref ore, sugges t a putative role for both
alpha-- and alpha s-mediated responses in the genesis of
reperfusion ventricular fibrillation. Because the protective
concentration of yohimbine, the alpha--antagonist , approx-
imated more closely its dissociation constant (using the ini-
tial value of Guicheney et al. [30], alpha j-re spon ses may
be more important than alpha- responses in the initiation of
reperfusion ventricular fibrillation . Although yohimbine has
nonspecific effects that could playa major role in this pro-
posed antiarrhythmic effect, our conclusions are of interest
as the antiarrhythmic potential of yohimbine has not yet
been emphasized.
Relation of protective concentrations of alpha-antag-
onist agents to the dissociation constants. The co ncen-
trations of alpha-adrenergic antagonist agent s that protected
aga inst reperfusion ventricular fibrillation appear relatively
high in comparison with the molar concentrations of the
displacement constant s of myocardial alpha, - and alpha j-
receptors. Factors that may account for this finding are:
aJ Displacement constants represent 50% of receptor
binding . Protection against ventricular fibrillation may re-
quire complete receptor binding , in which case high con-
centrations of antagonist agents would be necessary .
bJ Alpha ,-receptors increase in number in the cat heart
after the development of acute myocardial ischemia and on
reperfusion (32) . The concentrations of alpha .iadrenergic
antagonist agents required to exh ibit receptor antagonism
would, therefore, be correspondingly increased. No results
are available as to the changes of alpha- receptors after acute
ischemia and on reperfusion.
cJ Ligation of the left main coronary artery in the rat
results in extensive ischemia ofthe left ventricularfree wall.
This is thought to induce a marked local release of endog-
enou s noradrenalin in the ischemic myoca rdium which sup-
posedly may attain a concentration of I ILmollliter (33). To
achieve receptor antagonism, a correspondingly high con-
centration of antagonist agent may be necessary.
d} The protective effec t of alpha -antagonist agents may
be due to a nonspecific effect. Thus, Rosen et al. (34) showed
that phentolamine in concentrations of 10 ILmoUliter or greater
produces consistent electrophysio logic changes in canine
cardiac Purk inje fibers similar to those manifested by class
I antiarrhythmic agents that possess membrane-stabilizing
activity, namel y, decreased automati city and membrane re-
sponsiveness and increased conduction time , action poten-
tial duration and effective refracto ry period , respectively
(phentolamine , I ILmol/liter . did not consistently produce
these changes) . Furth er evidence that phentolamine may
exert a primary electrophysiologic effect stems from the
findings (35) that phentolamine prevented the reduction in
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effective refractory period during coronary occlusion as well
as the overshoot in the effective refractory period on re-
perfusion in the dog. These electrophysiologic changes were
associated with protection against reperfusion arrhythmias
in that dog model.
In our study, the concentration of phentolamine produc-
ing a 50% reduction in the incidence of reperfusion ven-
tricular fibrillation was 2.5 JLmollliter, with complete pro-
tection occurring at 50 JLmollliter. Therefore, it is not unlikely
that the protective effect of alpha-adrenergic antagonist agents
in our study may be dependent partly or completely on a
nonspecific effect, namely, membrane-stabilizing activity.
This proposal is strengthened by the finding that pretreat-
ment with reserpine reduced the duration of reperfusion
ventricular tachycardia-fibrillation.
Comment. The propensity of alpha-adrenergic antago-
nist agents to protect against reperfusion ventricular fibril-
lation is complex and may be dependent either on alpha--
and less so on alpha-receptor antagonism or on membrane-
stabilizing activity, or both.
Role of beta-adrenergic-mediated responses. Three
beta-adrenoceptor antagonists, atenolol, 30 JLmollliter; me-
toprolol, 10 JLmollliter, and propranolol, 0.5 JLmollliter,
displayed complete beta-antagonism against the cardiac ef-
fects of the beta-agonist, isoproterenol, O. I JLmollliter.
However, in these concentrations, all three agents were
ineffective in the prevention of ventricular fibrillation. In
higher concentration, atenolol, 100 JLmollliter, displayed no
protection, whereas metoprolol, 10 JLmollliter, and pro-
pranolol, 10 JLmollliter, respectively, exhibited marked pro-
tection. The common property shared by these high con-
centrations of metoprolol and propranolol (27) and lacking
in atenolol is membrane-stabilizing activity. The much higher
concentration of metoprolol required reflects its much lower
membrane-stabilizing activity. d-Propranolol, the propran-
olol isomer with dominant membrane-stabilizing activity
but with only some of the beta-antagonist activity of the
racemic mixture, showed protection against reperfusion-in-
duced fibrillation equivalent to that of equimolar racemic
dl-propranolol.
Comment. Our findings suggest that it is not the beta-
adrenergic antagonist activity itself that mediates protection
against reperfusion arrhythmias, but rather the membrane-
stabilizing activity possessed by some beta-adrenergic
antagonists.
Role of time of administration of drug in the preven-
tion of reperfusion ventricular fibrillation. Initiation of
antiarrhythmic therapy 5 minutes after coronary artery li-
gation (compared with initiation 5 minutes before coronary
ligation) shifted the dose-response curve of phentolamine
and metoprolol to the right. The relative inaccessibility of
drugs to receptor or membrane due to impaired coronary
perfusion may explain the necessity for high concentrations
when drug administration was begun after coronary ligation.
Major side effect. Drug concentrations of 10 JLmollliter
or greater resulted in a 25 to 40% reduction in heart rate.
Thus, in secondary antiarrhythmic prophylaxis (drug admin-
istration after the onset of ischemia), optimally protective
concentrations against reperfusion ventricular fibrillation may
not be achieved because of marked hemodynamic impair-
ment. Administration before the onset of ischemia, there-
fore, would be a more desirable approach in the prevention
of reperfusion ventricular fibrillation because a lower drug
concentration is then effective.
Relation between ventricular arrhythmias during
coronary occlusionand reperfusion. The incidence of re-
perfusion ventricular fibrillation appeared to depend in part
on the incidence or severity of ventricular arrhythmias dur-
ing the antecedent period of coronary artery occlusion. a)
The EDso values of alpha- and beta-antagonist agents for
reduction in the incidence of ventricular tachycardia during
coronary occlusion and reperfusion ventricular fibrillation,
respectively, were similar. b) The concentrations of alpha-
and beta-antagonist agents that exerted maximal antiar-
rhythmic activity during occlusion and on reperfusion were
similar.
Thus, although disparate electrophysiologic mechanisms
(36) have been considered to underlie ventricular arrhyth-
mogenesis during occlusion and after reperfusion, this study
demonstrates that a single mode of antiarrhythmic therapy
with phentolamine or metoprolol may be effective on ar-
rhythmias in both settings.
Effects on myocardial metabolism. We have proposed
that biochemical sequelae of acute myocardial ischemia may
predispose to arrhythmogenesis (3). Thus, shortening of the
action potential duration may arise from the reduction in
the glycolytic (l0) and mitochondrial (ll) production of
adenosine triphosphate, whereas slow response action po-
tentials are hypothetically related to the accumulation of
cyclic AMP in the ischemic tissue. In our study, some
circumstantial association was evident between improved
metabolic status on reperfusion and protection against re-
perfusion ventricular fibrillation (Table 3). Preservation of
high energy phosphate compounds may exhibit antiar-
rhythmic activity by maintenance of action potential dura-
tion and cell membrane integrity, thereby preventing the
proposed arrhythmogenic effect of Iysophosphoglycerides
(37). In addition, the lower levels of cyclic adenosine mono-
phosphate 10 seconds after reperfusion may possibly be a
factor in preventing reperfusion arrhythmias (38). However,
in our study, agents affording a similar degree of metabolic
preservation were associated with varying degrees of an-
tiarrhythmic activity (compare metoprolol, 100 JLmollliter
added 5 minutes after ligation and phentolamine and 10
JLmollliter added 5 minutes before coronary ligation). If
preservation of metabolic status plays a role in the mediation
of the antiarrhythmic effects, it is but one of several factors
involved.
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